Point72 Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Point72 Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-70,000	Closed	-$2.59M	–	1750
2022 Q3	$2.59M	Buy	+70,000	New	+$1.94M	0.01%	870

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management's RLMD Position: Q2 2026 in Review

Point72 Asset Management sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 504,820 shares — an estimated $3.51M sold.

Point72 Asset Management first reported a position in RLMD in Q4 2019 and held it in 15 quarters. The position peaked at $35.4M in Q1 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Point72 Asset Management reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
Point72 Asset Management sold 504,820 Relmada Therapeutics shares in Q2 2026, an estimated $3.51M.
Point72 Asset Management first reported a position in Relmada Therapeutics in Q4 2019 and held it in 15 quarters.
Point72 Asset Management's Relmada Therapeutics position peaked at $35.4M in Q1 2022.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.